United Therapeutics Corporation vs. Actelion Pharmaceuticals Ltd. et al.

Explore the PTAB proceeding IPR2025-01139 filed by United Therapeutics Corporation on 2025-06-10. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Proceeding Overview

Proceeding Number

IPR2025-01139

Filing Date

2025-06-10

Accorded Filing Date

2025-06-10

Institution Decision Date

2025-11-20

Last Modified Date

2026-01-09

Proceeding Type

IPR

Termination Date

2025-11-20

Trial Status

Discretionary Denial

Parties & Counsel

Petitioner

United Therapeutics Corporation

Represented By

Carsten, Douglaset al

Patent Owner / Respondent

Actelion Pharmaceuticals Ltd. et al.

Represented By

Broughan, Thomaset al

Tribunal & Venue

Tribunal

Patent Trial and Appeal Board (USPTO)

Technology Center

TC 1600 - Biotechnology & Organic Chemistry

Patent Information

1 Patent Involved

Respondent Application Number 12439290

Respondent Patent Number 8268847

External Links

Espacenet

Google Patents

Respondent Inventor Martine Clozel

Respondent Tech Center TC 1600 - Biotechnology & Organic Chemistry

Address and Attorney/Agent Information

70 Registered Practitioners

Power of Attorney & Correspondence

Firm / Entity Name BakerHostetler

Customer Number 45511

Address 1735 Market Street, Suite 3300, Philadelphia, PA, 19103-7501, UNITED STATES

Attorney / Agent Information

Reg #	Name	Phone
32019	Paul Coletti	908-230-8324
32501	Hal Woodrow	732-718-1308
32853	Robert Deberardine	908-981-6600
33124	Timothy Casey	206-332-1107
33277	Joel Rothfus	609-644-5734
33307	Joseph Lucci	215-564-8370
34294	William Bergmann	202-861-1549
35057	David Bailey	215-564-8956
35429	Christopher Arena	404-459-5644
36226	Joseph O'Malley	415-350-6823
37107	Louis Capezzuto	732-524-2218
37711	Steven Samuels	215-564-0564
38041	Michael Swope	206-332-1386
38435	Laura Donnelly	215-299-6135
39289	David Mancino	513-929-3495
39702	Robert Hails Jr	202-861-1754
41128	Mark Krietzman	310-375-2538
41483	Kimberly Prior	201-213-4422
44104	David Farsiou	215-564-3100
44248	John Mueller	513-929-3413
46018	Jeffrey Rosedale	215-568-3100
46603	Charles Carson	703-760-7709
46707	Adam Forman	215-568-3100
46785	Eve Frank	732-524-2797
47042	Felicity Groth	215-568-3100
47785	Jeremy Mckown	732-524-6250
47840	Tracy Palovich	215-564-2776
50224	Rakesh Mehta	302-984-6089
51430	Stephanie Lodise	215-564-8918
51493	Jason Brady	407-649-4003
51612	Erdal Dervis	202-861-1744
51647	Kenneth Eiferman	215-568-3100
52518	John Hilten	202-861-1500
53136	Kevin Kirsch	513-929-3499
54552	Timothy Worrall	720-931-1198
57289	Scott Conley	513-852-2611
57955	Charles Raphun	919-997-4436
58127	Timothy Doyle	215-564-1412
58402	Tayan Patel	202-496-7713
59932	Cory Davis	404-881-7258
59985	Donald Scaltrito	202-715-2898
61264	J. Galvez	215-628-6426
61943	Aaron Rabinowitz	215-568-3100
62835	David Hoffman	215-564-8376
63461	Jeffrey Lesovitz	215-564-8956
64253	Lisa Horninger	215-628-5052
64802	Scott Stanley	513-243-3020
65559	Theresa Weisenberger	215-568-3100
66382	Sean Brock	215-568-3100
67653	Jared Brandyberry	513-404-9712
67691	Brendan Clark	216-861-6488
68296	Jonathan Werner	202-861-1669
68488	Scott Simpkins	215-564-3008
69271	Brandon Mecham	215-564-3100
69862	Laura Gordon	215-564-2587
71482	Ronald Kern Jr.	215-564-1669
71906	Kevin Flynn	513-852-2627
72177	Cory Nesemann	407-649-4000
72909	Sofia Kopelevich	929-423-7401
74235	James Hatten	404-256-8242
74894	S. Sargsyan	404-256-8235
74904	Deborah Drazen	732-524-1976
75086	Alaina Lakawicz	215-564-2576
75310	Nikki Sanford	206-332-1399
76726	Mark Einsiedel	614-462-4709
77118	Michael Schwartz	215-568-3439
77712	Katharine Domitrovich	206-332-1112
79344	Anna Miron	617-937-2452
L0941	Aiqing Wang	206-903-2473
L0947	Yeojin Kuh	202-823-9089

Proceeding Documents

Notice: refund approved NOTICE

2026-01-09 FILING PARTY: BOARD

Download

Petitioner's Request for Refund of Post-Institution Fees OTHER

2026-01-06 FILING PARTY: PETITIONER

Download

Director Discretionary Decision: Deny RESPONSE

2025-11-20 FILING PARTY: BOARD

Download

Institution Decision: Deny DECISION

2025-10-31 FILING PARTY: BOARD

Download

2023

Stassi, D.L. et al., Ethyl-substituted erythromycin derivatives produced by directed metabolic engineering Exhibit

2025-10-01 FILING PARTY: PATENT OWNER

Download

United Therapeutics Corporation vs. Actelion Pharmaceuticals Ltd. et al.

Proceeding Overview

Parties & Counsel

Petitioner

United Therapeutics Corporation

Represented By

Patent Owner / Respondent

Actelion Pharmaceuticals Ltd. et al.

Represented By

Tribunal & Venue

Patent Information

Address and Attorney/Agent Information

Power of Attorney & Correspondence

Attorney / Agent Information

Proceeding Documents

Notice: refund approved NOTICE

Petitioner's Request for Refund of Post-Institution Fees OTHER

Director Discretionary Decision: Deny RESPONSE

Institution Decision: Deny DECISION

Stassi, D.L. et al., Ethyl-substituted erythromycin derivatives produced by directed metabolic engineering Exhibit

EX 1051 - Complaint 1:25-cv-15227-RMB-SAK Exhibit

Lee, S.H. & Channick, R.N., Endothelin Antagonism in Pulmonary Arterial Hypertension Exhibit

McLaughlin, V. et al., Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension Exhibit

Humbert, M. et al., Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 Exhibit

Paul, G.A., Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension Exhibit

EX 1053 - Baylor Declaration Exhibit

Revatio® Label Exhibit

Patent Owner Preliminary Response POPR

Adcirca® Label Exhibit

Jacobs, M., Mechanism of Action of Hydralzaine on Vascular Smooth Muscle, BIOCHEM. PHARMACOL. Exhibit

Petitioner's Response to PO's Request for Discretionary Denial RESPONSE

Rubin, L.J. et al., Bosentan Therapy for Pulmonary Arterial Hypertension Exhibit

Schneider, M.P. et al., Contrasting Actions of Endothelin ETA and ETB Receptors in Cardiovascular Disease Exhibit

EX 1052 - Ravi Declaration Exhibit

EX 1050 - Actelion Pending Litigation Exhibit

Nielsen-Kudsk, J.E. et al., K+ channel opening: a new drug principle in cardiovascular medicine, Exhibit

Petitioner's Updated Mandatory Notices NOTICE

Sica, D.A. & Gehr, T.W.B., Direct Vasodilators and their Role in Hypertension Management: Minoxidil, J. CLIN. HYPERTENSION Exhibit

Humbert, M. et al., Treatment of Pulmonary Arterial Hypertension Exhibit

Resnick, M.S. et al., Flosequinan, a vasodilator with a novel mechanism of action, Exhibit

Packer, M. et al., Double-Blind, Placebo-Controlled Study of the Efficacy of Flosequinan in Patients With Chronic Heart Failure Exhibit

Declaration of Dr. Luke Howard, DPhil MB BChir FRCP Exhibit

Hoeper, M. et al., Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension Exhibit

Orange Book Entry for OPSUMIT® Exhibit

Decision of Canadian Court in Janssen, Inc. et al. v. Sandoz Canada Inc. (Court File No. T-549-20), 2022 FC 715 (Fed. Ct. May 31, 2022), appeal dismissed, Sandoz Canada Inc. v. Janssen Inc. (No. A-128-22), 2023 FCA 221 (Fed. Ct. App. Nov. 9, 2023) Exhibit

Canadian Pat. No. 2,659,770 Exhibit

United Therapeutics Form 10K Annual Report for 2013 Exhibit

United Therapeutics, Our History Timeline Exhibit

A. Sertkaya et al., Costs of Drug Development and Research and Development Intensity in the US, 2000-2018, JAMA Network Open. 2024;7(6):e2415445 (June 8, 2024) Exhibit

OPSYNVI® (macitentan and tadalafil) Becomes the First and Only Health Canada-Approved Once Daily Fixed Dose Combination Treatment for Patients with Pulmonary Arterial Hypertension (PAH) (Oct. 15, 2021) Exhibit

Orange Book Entry for OPSYNVI® Exhibit

Claim 1 of the ’847 patent compared to CA ’770 patent Exhibit

Research and Development in the Pharmaceutical Industry, Congressional Budget Office (April 2021) Exhibit

FDA approves Opsumit to treat pulmonary arterial hypertension (Oct. 18, 2013) Exhibit

Clinicaltrials.gov entry to the A DUE study re: OPSYNVI® (macitentan/tadalafil in one dose) Exhibit

U.S. FDA Approves OPSYNVI® (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH) (Mar. 22, 2024) Exhibit

Clinicaltrials.gov entry for the SERAPHIN study re: OPSUMIT® (macitentan) Exhibit

Patent Owner's Request For Discretionary Denial Of Institution RESPONSE

Notice: Notice filing date accorded NOTICE

Patent Owner's Mandatory Notice NOTICE

Patent Owner Actelion Pharmaceuticals Ltd.'s Power of Attorney NOTICE

EX 1025 - Revatio Letter Exhibit

EX 1018 - Trachte Exhibit

EX 1028 - Seo 1994 Exhibit

EX 1039 - Kiowski 1991 Exhibit

EX 1002 - 847 Prosecution History Exhibit

EX 1024 - Bolli 2012 Exhibit

EX 1045 - Approval Letter Exhibit

EX 1020 - Daugan Exhibit

EX 1049 - Declaration of Brennen P. Baylor Exhibit

EX 1003 - 847 Reexam FH Exhibit

EX 1027 - Kedzierski 2001 Exhibit

EX 1037 - Forgue 2006 Exhibit

EX 1042 - Affuso 2006 Exhibit

EX 1006 - 13/604,148 FH Exhibit

EX 1030 - Henry 1999 Exhibit

Petition: as filed PETITION

EX 1038 - Cheng 2003 Exhibit

EX 1021 - Michelakis Exhibit

EX 1007 - Viagra Exhibit